Amphastar Pharmaceuticals, Inc. (AMPH)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 250M 500M 750M FY12: 204.3M FY13: 229.7M FY14: 210.5M FY15: 251.5M FY16: 255.2M FY17: 240.2M FY18: 294.7M FY19: 322.4M FY20: 349.8M FY21: 437.8M FY22: 499M FY23: 644.4M FY24: 732M FY25: 719.9M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 150M 300M 450M FY12: 90.3M FY13: 87M FY14: 51.3M FY15: 77.3M FY16: 104.2M FY17: 90.5M FY18: 107M FY19: 131.9M FY20: 143.3M FY21: 199.7M FY22: 248.9M FY23: 351.1M FY24: 373.9M FY25: 356.1M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

-70M 0 70M 140M 210M FY12: 25.4M FY13: 17.5M FY14: -18M FY15: -6.9M FY16: 15.4M FY17: -1.3M FY18: -8.6M FY19: -39K FY20: 11M FY21: 69.9M FY22: 107.5M FY23: 197M FY24: 205.4M FY25: 140.4M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-60M 0 60M 120M 180M FY12: 18.1M FY13: 11.9M FY14: -10.7M FY15: -2.8M FY16: 9.8M FY17: 3.6M FY18: -5.7M FY19: 48.9M FY20: 1.4M FY21: 62.1M FY22: 91.4M FY23: 137.5M FY24: 159.5M FY25: 98.1M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 150M 300M 450M FY12: 114M FY13: 142.7M FY14: 159.2M FY15: 174.2M FY16: 151M FY17: 149.7M FY18: 187.7M FY19: 190.4M FY20: 206.5M FY21: 238M FY22: 250.1M FY23: 293.3M FY24: 358.1M FY25: 363.8M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

-80M 0 80M 160M 240M FY12: -1.6M FY13: 31M FY14: 21.1M FY15: 10.7M FY16: 38.6M FY17: 39.2M FY18: 38.2M FY19: 41.8M FY20: 57.3M FY21: 98M FY22: 89.2M FY23: 183.5M FY24: 213.4M FY25: 156.1M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-60M 0 60M 120M 180M FY12: -24.8M FY13: 13.4M FY14: 553K FY15: -5.3M FY16: 17.2M FY17: 4.1M FY18: -8.6M FY19: 207K FY20: 23.4M FY21: 70.5M FY22: 65.1M FY23: 145.3M FY24: 172.3M FY25: 121.2M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 20M 40M 60M FY12: 38.9M FY13: 38.9M FY14: 42M FY15: 45M FY16: 47.5M FY17: 48.4M FY18: 46.4M FY19: 49.9M FY20: 49.1M FY21: 49.8M FY22: 52.4M FY23: 53M FY24: 52.1M FY25: 48.2M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 0.00 1.50 3.00 4.50 Q4 '13: 0.31 Q1 '14: 0.21 Q2 '14: -0.02 Q3 '14: -0.14 Q4 '15: -0.07 Q1 '16: -0.01 Q2 '16: 0.29 Q3 '16: 0.44 Q4 '16: 0.22 Q1 '17: 0.19 Q2 '17: 0.08 Q3 '17: 0.00 Q4 '17: 0.08 Q1 '18: -0.09 Q2 '18: -0.19 Q3 '18: -0.14 Q4 '18: -0.12 Q1 '19: 0.05 Q2 '19: 1.07 Q3 '19: 1.05 Q4 '19: 0.99 Q1 '20: 1.05 Q2 '20: 0.09 Q3 '20: 0.14 Q4 '20: 0.03 Q1 '21: 0.05 Q2 '21: 0.21 Q3 '21: 0.72 Q4 '21: 1.25 Q1 '22: 1.62 Q2 '22: 1.79 Q3 '22: 1.50 Q4 '22: 1.75 Q1 '23: 1.78 Q2 '23: 1.94 Q3 '23: 2.55 Q4 '23: 2.59 Q1 '24: 2.90 Q2 '24: 3.14 Q3 '24: 3.01 Q4 '24: 3.06 Q1 '25: 2.76 Q2 '25: 2.67 Q3 '25: 2.26 Q4 '25: 2.03 Q1 '26: 1.66 Q2 '26: 1.69 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.